Avacta Group plc (LSE:AVCT) has published new preclinical pharmacology data for its tumour-targeted drug candidate FAP-Exd (AVA6103), highlighting its potential to deliver highly potent cancer therapy directly within tumour tissue. The candidate is designed to release a topoisomerase I inhibitor selectively in the tumour microenvironment, with the aim of improving efficacy while limiting systemic exposure.
The data demonstrated increased tumour-specific cell killing, sustained intratumoural drug release lasting up to five days, and durable anti-tumour responses across preclinical models. Avacta also noted that artificial intelligence has been applied to clinical trial design, helping to optimise patient selection and streamline development. The programme is now being prepared for a Phase 1 clinical trial, targeted to begin in early 2026.
Despite the positive scientific and development milestones, the group continues to face notable financial and valuation pressures. Ongoing losses and dependence on external funding remain key challenges, even as recent technical signals and corporate progress offer some support to the longer-term investment case.
More about Avacta Group plc
Avacta Group plc is a clinical-stage biopharmaceutical company developing novel oncology treatments based on its proprietary pre|CISION® platform. The technology uses tumour-specific protease activation to deliver highly potent drug payloads directly to cancer cells, with the goal of improving therapeutic outcomes while reducing damage to healthy tissue.
Leave a Reply